International Circulation:  Finally， the effect of aliskiren on organ damage and clinical outcomes is being assessed in the ongoing APSIRE HIGHER program， which is the largest clinical trial program in the cardio-renal disease area.  We have results from the ALOFT， ALAY， and ANGEL studies that would suggest it has positive effects on markers of cardiovascular and renal damage in patients with type II diabetes， nephropathy， heart failure， left ventricular hypertrophy， and also the elderly.  Do these previous studies suggest or are predictive of the ASPIRE HIGHER program’s results?  What is your opinion?